Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apatinib + doxorubicin + ifosfamide
- Development stage
- Unknown
- Lead developer
- Sun Yat-sen University
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination therapy consists of apatinib (apatinib mesylate), doxorubicin, and ifosfamide, and is being investigated for the treatment of advanced or metastatic soft tissue sarcoma (STS). Apatinib is a small molecule tyrosine kinase inhibitor that selectively targets vascular endothelial growth factor receptor-2 (VEGFR-2), thereby inhibiting tumor angiogenesis. Doxorubicin is an anthracycline antibiotic that acts as a cytotoxic agent by intercalating into DNA and inhibiting topoisomerase II, leading to DNA damage and cell death. Ifosfamide is a nitrogen mustard alkylating agent that cross-links DNA, interfering with replication and transcription. This triplet regimen, notably studied at Sun Yat-sen University Cancer Center, aims to enhance therapeutic efficacy in sarcoma subtypes by combining targeted anti-angiogenic effects with standard cytotoxic chemotherapy.
- Other names
- Apatinib Mesylate combined with Doxorubicin and IfosfamideApatinib + Doxorubicin + Ifosfamide in Advanced STS
02
Targets
TOP2A (DNA topoisomerase II)VEGFR2 (Vascular endothelial growth factor receptor 2)DNA
Beyond the preview
Go deeper on apatinib + doxorubicin + ifosfamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apatinib + doxorubicin + ifosfamide.